Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BioLineRx Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Phil Serlin

İcra Kurulu Başkanı

US$952.0k

Toplam tazminat

CEO maaş yüzdesi	29.4%
CEO görev süresi	8yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	7.7yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Phil Serlin'un ücretlendirmesi BioLineRx'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$952k	US$280k	-US$61m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$43m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$1m	US$297k	-US$25m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$903k	US$290k	-US$27m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$34m
Dec 31 2020	US$958k	US$250k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$678k	US$256k	-US$25m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$846k	US$254k	-US$23m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$26m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$612k	US$240k	-US$24m

Tazminat ve Piyasa: Phil 'nin toplam tazminatı ($USD 952.00K ), IL pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 429.76K ).

Tazminat ve Kazançlar: Phil 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Phil Serlin (64 yo)

8yrs

Görev süresi

US$952,000

Tazminat

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philip Serlin	Chief Executive Officer	8yrs	US$952.00k	0.014% $ 26.3k
Mali Zeevi	Chief Financial Officer	8yrs	US$443.00k	0.027% $ 50.3k
Ella Sorani	Chief Development Officer	7.7yrs	US$520.00k	0.0055% $ 10.1k
Holly May	President of BioLineRx USA	2.3yrs	US$1.01m	Veri yok
John Lacey	Head of Corporate Communications & Investor Relations	no data	Veri yok	Veri yok
Tsipi Keren-Lehrer	Head of BD & Strategic Advisor	5.2yrs	Veri yok	Veri yok
Raziel Fried	Treasurer & Budgetary Control Director	no data	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: BLRX 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Aharon Schwartz	Chairman of the Board	20.8yrs	Veri yok	0.31% $ 566.9k
Sandra Panem	Director	10.7yrs	Veri yok	Veri yok
Avraham Molcho	Independent External Director	14.3yrs	US$26.55k	Veri yok
Raphael Hofstein	Director	21.8yrs	US$140.92k	Veri yok
Ronald Levy	Member of Immuno-Oncology Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Rami Dar	Independent External Director	2.3yrs	Veri yok	Veri yok
Gal Cohen	Independent Director	less than a year	Veri yok	Veri yok
Barbar-Jean Bormann-Kennedy	Director	11.2yrs	Veri yok	Veri yok
Jon Marc Wigginton	Member of Immuno-Oncology Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Ignacio Melero Bermejo	Member of Immuno-Oncology Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Aurelien Marabelle	Member of Immuno-Oncology Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Shaoyu Yan	Director	less than a year	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BLRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

BioLineRx Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

Less than half of directors are independent

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

Recent updates

New major risk - Revenue and earnings growth

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

New major risk - Financial position

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

New major risk - Share price stability

New major risk - Revenue and earnings growth

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

New minor risk - Market cap size

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

New major risk - Shareholder dilution

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

New minor risk - Shareholder dilution

BioLineRx Ltd. announced that it has received $14.6 million in funding

New minor risk - Market cap size

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

New major risk - Financial position

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

Less than half of directors are independent

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

Is BioLineRx (TLV:BLRX) A Risky Investment?

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

Less than half of directors are independent

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Forecast breakeven pushed back to 2024

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

New 90-day high: ₪0.82

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

New 90-day high: ₪0.66

BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020

BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

New 90-day low: ₪0.36

New 90-day low: ₪0.37

BioLineRx Ltd. has completed a Follow-on Equity Offering.

BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020

CEO Tazminat Analizi

CEO

Görev süresi